Andrew J Peat

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9265026/publications.pdf

Version: 2024-02-01

36	1,803	22	36
papers	citations	h-index	g-index
36	36	36	2128
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Rational Design to Large-Scale Synthesis: Development of GSK8175 for the Treatment of Hepatitis C Virus Infection. ACS Symposium Series, 2019, , 297-322.	0.5	2
2	Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Clinical Effect of Danirixin in Adults With Acute, Uncomplicated Influenza. Open Forum Infectious Diseases, 2019, 6, ofz072.	0.9	16
3	Efficacy and Safety of Danirixin (GSK1325756) Co-administered With Standard-of-Care Antiviral (Oseltamivir): A Phase 2b, Global, Randomized Study of Adults Hospitalized With Influenza. Open Forum Infectious Diseases, 2019, 6, ofz163.	0.9	20
4	Open-Air Alkylation Reactions in Photoredox-Catalyzed DNA-Encoded Library Synthesis. Journal of the American Chemical Society, 2019, 141, 3723-3732.	13.7	250
5	Design of <i>N</i> -Benzoxaborole Benzofuran GSK8175—Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor. Journal of Medicinal Chemistry, 2019, 62, 3254-3267.	6.4	40
6	Multi-Modal Imaging with a Toolbox of Influenza AReporter Viruses. Viruses, 2015, 7, 5319-5327.	3.3	40
7	Encoded Library Technology Screening of Hepatitis C Virus NS4B Yields a Small-Molecule Compound Series with <i>In Vitro</i> Replicon Activity. Antimicrobial Agents and Chemotherapy, 2015, 59, 3450-3459.	3.2	29
8	Preclinical Characterization and <i>In Vivo</i> Efficacy of GSK8853, a Small-Molecule Inhibitor of the Hepatitis C Virus NS4B Protein. Antimicrobial Agents and Chemotherapy, 2015, 59, 6539-6550.	3.2	10
9	Design and synthesis of spirocyclic compounds as HCV replication inhibitors by targeting viral NS4B protein. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2288-2294.	2.2	22
10	Hepatitis C Replication Inhibitors That Target the Viral NS4B Protein. Journal of Medicinal Chemistry, 2014, 57, 2107-2120.	6.4	45
11	Discovery of a Potent Boronic Acid Derived Inhibitor of the HCV RNA-Dependent RNA Polymerase. Journal of Medicinal Chemistry, 2014, 57, 1902-1913.	6.4	46
12	Rational Design of Potent Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. Journal of Medicinal Chemistry, 2012, 55, 10601-10609.	6.4	48
13	Imidazo[1,2- <i>a</i>) pyridines That Directly Interact with Hepatitis C NS4B: Initial Preclinical Characterization. ACS Medicinal Chemistry Letters, 2012, 3, 565-569.	2.8	45
14	Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 981-985.	2.2	8
15	Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 976-980.	2.2	8
16	Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1177-1182.	2.2	18
17	Solid phase synthesis and SAR of small molecule agonists for the GPR40 receptor. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 1584-1589.	2.2	66
18	6-(4-Chlorophenyl)-3-substituted-thieno[3,2-d]pyrimidin-4(3H)-one-Based Melanin-Concentrating Hormone Receptor 1 Antagonist. Journal of Medicinal Chemistry, 2006, 49, 7108-7118.	6.4	20

#	Article	IF	CITATIONS
19	Potent, Selective, and Orally Efficacious Antagonists of Melanin-Concentrating Hormone Receptor 1. Journal of Medicinal Chemistry, 2006, 49, 7095-7107.	6.4	34
20	Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. British Journal of Pharmacology, 2006, 148, 619-628.	5.4	359
21	Synthesis and activity of small molecule GPR40 agonists. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 1840-1845.	2.2	104
22	Synthesis and evaluation of novel heterocyclic inhibitors of GSK-3. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 2091-2094.	2.2	44
23	The discovery and optimization of pyrimidinone-containing MCH R1 antagonists. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 4723-4727.	2.2	44
24	A Novel One-Pot Synthesis of N-Substituted Thieno [3,2-d] pyrimidin-4(3H)-ones. Heterocycles, 2006, 70, 587.	0.7	2
25	Novel pyrazolopyrimidine derivatives as GSK-3 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 2121-2125.	2.2	62
26	3-Trifluoromethyl-4-nitro-5-arylpyrazoles are novel KATP channel agonists. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 813-816.	2.2	13
27	Novel GSK-3 inhibitors with improved cellular activity. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 2127-2130.	2.2	47
28	Synthesis and evaluation of 7-substituted-3-cyclobutylamino-4H-1,2,4-benzothiadiazine-1,1-dioxide derivatives as KATP channel agonists. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 2977-2980.	2.2	12
29	A Combined Zirconocene Benzyneâ^Palladium Cross-Coupling Route to Substituted Biphenyls and Terphenyls. Journal of the American Chemical Society, 1999, 121, 9469-9470.	13.7	36
30	Titanocene-Based Method for Indole Synthesis. Journal of the American Chemical Society, 1998, 120, 3068-3073.	13.7	71
31	Regioselective, Directed Meta Acylation of Aromatic Compounds. Journal of the American Chemical Society, 1998, 120, 9119-9125.	13.7	28
32	Novel Syntheses of Tetrahydropyrroloquinolines:Â Applications to Alkaloid Synthesis. Journal of the American Chemical Society, 1996, 118, 1028-1030.	13.7	117
33	Synthesis and Reactions of 3-(Bromomethyl)-1-carbethoxy-4-iodoindole: The Preparation of 3,4-Differentially Substituted Indoles. Journal of Organic Chemistry, 1994, 59, 7164-7168.	3.2	46
34	Conformational preferences of C1-oxygenated acyclic chiral alkenes: The effect of vinyl and allyl substituents. Tetrahedron Letters, 1993, 34, 1417-1420.	1.4	17
35	An anomalous case of diastereofacial selectivity in the addition of chiral allylstannanes to benzaldehyde: is the "inside alkoxy―effect involved?. Tetrahedron Letters, 1991, 32, 453-456.	1.4	28
36	Synthesis of Nonracemic 2-Vinyl-monoprotected 1,3-Diols from the Reactions of Chiral Allylstannanes with Aldehydes. Synthetic Communications, 1991, 21, 1797-1802.	2.1	6